期刊文献+

小于等于59岁前列腺癌患者的临床特点及其预后分析 被引量:1

Clinical features and prognostic analysis in prostate cancer patients under 59 years of age: a report of 72 cases
原文传递
导出
摘要 目的探讨72例≤59岁前列腺癌患者临床及病理特点、生存率和影响预后的因素。方法2000年1月至2011年10月天津医科大学附属天津肿瘤医院收治前列腺癌患者566例,≤59岁前列腺癌72例(12.7%),具备完整临床病理资料。中位随访时间25个月(1—108个月),中位年龄55岁(16—59岁)。临床分期Ⅱ期4例(5.5%)、Ⅲ期12例(16.7%)、IV期56例(77.8%)。观察无进展生存率(PFS)、总生存率(OS),分析临床特点及影响预后的因素。结果病理类型腺癌占86.1%(62/72),Gleason评分8-10分占69.1%(29/42);特殊类型癌占13.9%(10/72)。内分泌治疗后,经中位12个月进展为雄激素非依赖性前列腺癌。中位无进展生存期13个月,1、3、5年PFS分别为53.8%、12.1%和6.1%;中位生存期39.6个月,1、3、5年OS分别为85.2%、58.8%和15.6%。单因素分析显示,年龄、基线PSA、病理类型、肿瘤分期和是否局部治疗是影响预后因素;多因素分析显示,病理类型是影响预后的独立因素。结论我国≤59岁前列腺癌临床易漏、误诊,病理类型复杂,恶性程度较高,以局部治疗为主的综合治疗是有效治疗手段。 Objective To explore the clinicopathological characteristics and prognostic factors in prostate cancer patients under 59 years of age. Methods From January 2000 to October 2011, 566 prostate cancer patients underwent treatments. Among them, 72 ( 12.7% ) patients under 59 years of age with the integrated clinical data were reviewed. The median follow-up period was 25 months (range:l - 108) and the median age 55 years (range:16 -59). Four (5.5%) cases had the clinical stage of I[ , 12(16. 7% ) cases of stage II1 and 56(77.8% ) cases of stage IV. Progression-free survival (PFS), overall survival (OS) and prognostic factors were analyzed. Results The rate of adenocarcinoma was 86. 1% ( 62/72 ) and the Gleason score of 8 -10 69. 1% (29/42). Special type carcinoma accounted for 13.9% (10/72). The median time to androgen-independent prostate cancer (AIPC) was 12 months after endocrine therapy. The 1-, 3- and 5-year PFS were 53.8% , 12. 1% and 6. 1% and those for OS 85.2% , 58. 8% and 15.6% respectively. The prognostic factors were age, baseline prostate special antigen (PSA), types of pathology, tumor stage and local treatment by univariate analysis. The type of pathology was an independent prognostic factor of affecting significantly the prognosis by multivariate analysis. Conclusion Prostate cancer patients under 59 years of age are characterized by misdiagnosis, complexity of pathology and high malignancy. Comprehensive regiment with predominant local therapy is an effective approach.
出处 《中华医学杂志》 CAS CSCD 北大核心 2012年第19期1300-1303,共4页 National Medical Journal of China
基金 国家自然科学基金(30973438) 国家青年科学基金(81001002) 天津市应用基础及前沿技术研究计划(09JCYBJC10400) 天津市卫生局科技基金(2010KZ71)
关键词 前列腺肿瘤 预后 治疗结果 年龄因素 Prostatic neoplasms Prognosis Treatment outcome Age factors
  • 相关文献

参考文献15

  • 1Lowe FC, Gilbert SM, Kahane H. Evidence of increased prostate cancer detection in men aged 50 to 59: a review of 324,684 biopsies performed between 1995 and 2002. Urology, 2003,62 : 1045-1049. 被引量:1
  • 2Welch HG, Albertsen PC. Prostate cancer diagnosis and treatment after the introduction of prostate-specific antigen screening: 1986- 2005. J Natl Cancer Inst,2009,101:1325-1329. 被引量:1
  • 3Neppl-Huber C, Zappa M, Coebergh JW, et al. Changes in incidence, survival and mortality of prostate cancer in Europe and the United States in the PSA era: additional diagnoses and avoided deaths. Ann Oncol,2011. [Epub ahead of prim]. 被引量:1
  • 4Coleman RE. Metastatic bone disease : clinical features, pathophysiology and treatment strategies. Cancer Treat Rev,2001, 27 : 165-176. 被引量:1
  • 5Terakedis BE, Rossi PJ, Liauw SL, et al. A surveillance, epidemiology, and end results registry analysis of prostate cancer modality time trends by age. Am J Clin Oncol,2010,33:619-623. 被引量:1
  • 6陈万青,张思维,郑荣寿,雷正龙,李光琳,邹小农,赵平.中国肿瘤登记地区2007年肿瘤发病和死亡分析[J].中国肿瘤,2011,20(3):162-169. 被引量:329
  • 7Lin DW, Porter M, Montgomery B. Treatment and survival outcomes in young men diagnosed with prostate cancer: a Population-based Cohort Study. Cancer,2009,115:2863-2871. 被引量:1
  • 8Scosyrev E, Messing EM, Mohile S, et al. Prostate cancer in the elderly : Frequency of advanced disease at presentation and disease- specific mortality. Cancer,2011. [Epub ahead of print]. 被引量:1
  • 9Datta MW, Dhir R, Dobbin K, et al. Prostate cancer in patients with screening serum prostate specific antigen values less than 4.0 ng/dl:resuhs from the cooperative prostate cancer tissue resource. J Urol,2005,173 : 1546-1551. 被引量:1
  • 10Nelson WG, De Marzo AM, Isaacs WB. Prostate cancer. N Engl J Med ,2003,349:366-381. 被引量:1

二级参考文献10

共引文献328

同被引文献19

  • 1范欣荣,李汉忠,石冰冰,纪志刚,夏溟,肖河,严维刚,周毅.多西他赛联合泼尼松治疗激素难治性前列腺癌的近期疗效观察[J].中华医学杂志,2007,87(24):1666-1668. 被引量:5
  • 2Tannock IF, Osoba D, Stockier MR, et al. Chemotherapy with mitoxantrone plus prednisone or prednisone alone for symptomatic Hormone-resistant prostate cancer: a canadian randomized trial with palliative end points. J Clin Oncol, 1996, 14:1756-1764. 被引量:1
  • 3Tannock IF, Wit R, Berry WR, et al. Docetaxel plus prednisone or mitoxantroneplus prednisone for advanced prostate cancer. N Engl J Med, 2004,351:1502-1512. 被引量:1
  • 4Berthold DR, Pond GR, Soban F, et al. Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer: updated survivalin the TAX 327 study. J Clin Oncol, 2008, 26:242-245. 被引量:1
  • 5Bono JS, Oudard S, Ozguroglu M, et al. Prednisone plus cabazitaxel or mitoxantrone for metastaticcastration-resistant prostate cancer progressing after docetaxel treatment : a randomised open-label trial. Lancet,2010, 376: 1147-1154. 被引量:1
  • 6Kuroda K, Liu H, Kim S, et al. Docetaxel down-regulates the expression of androgen receptorand prostate-specific antigen but not prostate-specific membrane antigenin prostate cancer cell lines: Implications for PSA surrogacy. Prostate, 2009, 69: 1579-1585. 被引量:1
  • 7Gan L, Chen S, Wang YW, et al. Inhibition of the androgen receptor as a novel mechanismof taxol chemotherapy in prostate cancer. Cancer Res, 2009, 69:8356-8394. 被引量:1
  • 8Zhu ML, Horbinski CM, Garzotto M, et al. Tubulin-targeting chemotherapy impairs androgen receptor activity in prostate cancer. Cancer Res, 2010, 70:7992-8002. 被引量:1
  • 9Tang Y, Khan MA, Goloubeva O, et al. Docetaxel followed by castration improves outcomes in LNCaP prostate cancer-bearing severe combined immunodeficient mice. Clin Cancer Res, 2006, 12 : 169-174. 被引量:1
  • 10曹希亮,高江平,韩刚,文载律,洪宝发,张旭.前列腺癌中垂体肿瘤转化基因表达及内分泌治疗后前列腺癌无进展生存期预测因素的研究[J].中华泌尿外科杂志,2009,30(9):609-613. 被引量:5

引证文献1

二级引证文献2

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部